SVB Leerink analyst Marc Goodman notes that it has been a "tough late summer/fall" for GW Pharmaceuticals, as misplaced investor concerns have beaten up the stock significantly and Friday was no different. The analyst points out that the concern on Friday started as investors checked on the weekly Symphony Rx data for the first week of October, which indicated a significant decline from the previous week. He was able to confirm with the company that a "very significant specialty pharmacy" had stopped reporting weekly Rxs to the data providers that flow into Symphony Rx, which makes sense given the surprisingly abrupt Rx trend on Friday. Goodman still believes Epidiolex can be a "significant" product in epilepsy. He reiterates an Outperform rating on the shares.